Since targeting multiple pathways involved in cancer development with a single compound represents a well-investigated approach to develop new cancer treatments [18], we investigated MV1035 ability to inhibit both ALKBH5 and ALKBH2 aiming to find a new drug able to hamper GBM progression and/or support TMZ therapy; in fact, combination therapy, especially for the most difficult to treat cancers, remains a keystone in therapy. Here, ALKBH2 is linked to glioblastoma.